Larvol Delta - Greenfire-Bio-to-update-progress-on-Phase-1-Clinical-Trial-for-SIK2SIK3-inhibitor-GRN300-in-ovarian-cancer-at-the-ASCO-Annual-Meeting-2022

GRN300 - Greenfire Bio

https://www.prnewswire.com/news-releases/greenfire-bio-to-update-progress-on-phase-1-clinical-trial-for-sik2sik3-inhibitor-grn-300-in-ovarian-cancer-at-the-asco-annual-meeting-2022-301558372.html

May 31, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next